TP53 and acute myeloid leukemia: While conventional clinical tests, such as blast counts in bone marrow or blood failed to detect progression of the disease after BMT compared to pre-BMT (Supplementary Table 4A), single-cell DNA-seq data successfully unveiled disease progression from pre-BMT to AML relapse as indicated by the expansion of the mutant TP53 oncogenic clone of cells (Fig. 1C).